This document is authorized for educator review use only by Gregory Theyel, California State University – East Bay until May 2018. Copying or posting is an infringement of copyright.
Exhibit 2 Company Milestones
1996 Merger of Ciba-Geigy and Sandoz to create one of the largest healthcare companies
2002 Novartis Institutes for Biomedical Research (NIBR) is created, headquartered in the United States
2003 Acquisition of Mead Johnson & Co., a subsidiary of Bristol-Myers Squibb
2004 Novartis submits Xolair for EU approval for treatment of allergic asthma
NIBR announces joint project with the Broad Institute of MIT and Harvard to research type 2 diabetes
2005 Landmark trial on Gleevec/Glivec, to treat chronic myeloid leukemia, shows 90% of patients still alive after four years of treatment
Aclasta gains EU regulation approval for treatment of Paget’s bone disease
Acquired North American over the counter brand portfolio of Bristol-Myers Squibb, expanding Novartis’ presence
2006 Strategic biomedical R&D center opens in Shanghai
Novartis Institute for Tropical Disease (NITD) initiates research on malaria. Through partnership with World Health Organization (WHO), provides anti-malarial Coartem, for no charge in developing nations
Omnitrope receives European Commission approval; 1st product approved under the EU’s new regulatory pathway for follow-on biological products
2007 Completed non-core divestments of the Gerber and Medical Nutrition Business units to Nestlé for $5.5 billion and $2.5 billion, respectively
Ranked No. 1 among pharmaceutical companies in Fortune magazine’s “World’s Most Admired Companies” survey
2008 Novartis announced an agreement to acquire 25% interest in Alcon, Inc., world leader in eye care with pharmaceutical, surgical, and consumer products (majority ownership acquired in 2010 and 100% in 2011)
Opened new vaccine research institute in Siena, Italy
Named healthcare super sector leader in the 2008 update of the Dow Jones Sustainability World Index
2009 Novartis became the first company to produce influence A (H1N1) vaccines with modern cell-culture biotechnology
Announced $1 billion investment over five years in China to build the largest pharmaceutical R&D institute in China
2010 Joseph Jimenez was named CEO
FDA approved Gilenya as the first oral treatment for relapsing-remitting multiple sclerosis
2011 Vaccines and medicines from Novartis reach an estimated $1 billion patients
Ranked No. 1 among pharmaceutical companies in Fortune magazine’s “World’s Most Admired Companies” survey
PLACE THIS ORDER OR A SIMILAR ORDER WITH NURSING TERM PAPERS TODAY AND GET AN AMAZING DISCOUNT
